INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...

Lilly's shares fall 8% as drug sales miss expectations CEO David Ricks cited physical and financial constraints at wholesalers for the shortfall Lilly slashes annual profit forecast due to ...

(AP Photo/Darron Cummings, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street ...

Wednesday’s dive came as Eli Lilly’s results released at about 7 a.m. EDT were worse than analyst expectations across the board, headlined by its $11.4 billion in Q3 sales (5% below forecasts ...

(Bloomberg) -- Eli Lilly & Co. lowered guidance Wednesday on lackluster sales of its weight-loss drug, which posted a shocking first miss that raised questions about the seemingly insatiable demand ...

Lilly’s success story “has been driven by demand vastly exceeding supply for its Mounjaro/Zepbound franchise, so a combined third-quarter sales miss of nearly $900 million as supply ...

However, analysts were looking for greater sales of the blockbuster drugs. Lilly swung to a profit of $970.3 million, or $1.07 per share, but still well below the $1.69 billion and $1.87 per share ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on ...

Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by ...

(Reuters) -Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third ...

On Wednesday, Eli Lilly and Co (NYSE:LLY ... compared to $0.10 from a year ago and missing the consensus of $1.45. Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ...